On April 2, 2018 -Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) has accepted the abstract titled "ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)" for a poster discussion at their annual meeting to be held June 1-5, 2018 in Chicago (Press release, Advaxis, APR 2, 2018, View Source [SID1234525108]). The discussion will be presented and lead by author and principle investigator of the study, Mark Stein, MD, medical oncologist at Columbia University Medical Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: "ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)"
Abstract Number:

5019
Session:

Genitourinary (Prostate) Cancer
Date:

June 2, 2018 4:45 PM-6:00 PM
Presenter:

Mark Stein, MD